Enfortumab vedotin with pembrolizumab for treating bladder cancer

Enfortumab vedotin in combination with pembrolizumab is in clinical development as a
neoadjuvant treatment option for cisplatin eligible patients with non-metastatic muscle invasive
bladder cancer (MIBC). MIBC is a cancer that spreads into the muscle layer of the bladder wall.
The survival rates for patients with MIBC are low because this type of cancer is more likely to
spread to other parts of the body. There is therefore a need to develop additional treatment
options to improve prognosis outcomes.